Skip to main content
Industry News
DPP-4 inhibitors raise bullous pemphigoid risk in T2D
8/10/2020

The risk for developing the skin condition bullous pemphigoid was higher among patients with type 2 diabetes who used dipeptidyl peptidase-4 inhibitors, compared with those who used second-generation sulfonylureas, according to a study in JAMA Dermatology. The cohort study of 1,664,880 patients with type 2 diabetes also revealed a greater association between increased risk of bullous pemphigoid and DPP-4 inhibitors, compared with sulfonylureas, among those who were white, 65 years or older and linagliptin users.

Full Story: